NeuroMab™ Anti-Tau BBB Shuttle Antibody(NRZP-1022-ZP3077)

Figure 1 Western blotting (WB) analysis of general Tau antibody display in brain lysates from Alzheimer's disease (AD) and matched control donors.

Figure 2 Tau capture ELISA.

Figure 3 shows the pharmacokinetics in mice following a single 10mg/kg intravenous or intraperitoneal injection of anti-Tau antibody.

Figure 4 shows that the change over time is flat in macaques following a single IV injection of 50 mg/kg of specific antibodies.

Figure 5 shows the concentration of antibodies in the hippocampus of rhesus monkeys at various time points after a single IV injection of 50 mg/kg of the indicated antibodies in rhesus monkeys.

Figure 6 shows, on a logarithmic scale, specific antibody injections at different time points after a single IV antibody concentration of 50 mg/kg in the macaque brain.

Figure 7 shows the concentration of total Tau in plasma and the concentration of macaque starch antibody in blood after a single IV injection of 50 mg/kg of a specific antibody in macaques.

Figure 8 is the plasma antibody concentration after a single intravenous injection of 50 mg/kg specific antibody in rhesus monkeys.